IL6 and interstitial lung disease: Lee et al. [30] demonstrated that serum IL-6 might be utilized as a biomarker to predict AE in ILD with different diagnoses, including IPF (68.7%), CTD (14.5%), cryptogenic organizing pneumonia (9.6%), non-specific interstitial pneumonia (6.0%), and hypersensitivity pneumonitis (1.2%).